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Non-ISH Systolic-diastolic hypertension or isolated diastolic hypertension 
PP Pulse pressure 
SBP Systolic blood pressure 
SD Standard deviation 
SHEP The systolic hypertension in the elderly program 
Syst-China The systolic hypertension in China trial 
Syst-Eur The systolic hypertension in Europe trial 
UACR Urine albumin-creatinine ratio 
USA United States of America 
  
Page | 9  
 
Introduction 
 
The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study is a large 
randomized, comparative, antihypertensive treatment trial in patients with hypertension and 
ECG-LVH. The database includes standardized, detailed analyses of >100 000 12-lead 
ECGs taken during the course of the study. Though the study was not primarily designed to 
address this issue, prespecified secondary analyses provided a unique opportunity to study 
the effects of ECG-LVH regression on cardiovascular outcomes in a group of hypertensive 
patients with especially high risk, namely the isolated systolic hypertension (ISH) subgroup. 
Defined here as having SBP ≥160 mm Hg and DBP <90 mm Hg1-3, these patients all had 
high pulse pressure (PP) (mean 92 mm Hg at baseline), a marker of arterial stiffness, which 
has been associated with increased risk of developing atrial fibrillation (AF). Thorough 
analyses of these issues could provide insight into possible treatment goals in the prevention 
of cardiovascular morbidity and mortality in these high-risk patients, beyond that of 
lowering BP, and perhaps, further insight into development of atrial fibrillation in 
hypertension. 
 
Isolated systolic hypertension 
ISH is the most common form of hypertension in the elderly >60 years, accounting for 60-
75% of cases4;5, and is a major cardiovascular risk factor6-9.  
The pathogenesis of ISH is not completely understood, but mechanisms are most 
likely age-associated and potentially associated with lifestyle10. Evidence suggests that 
increased arterial vascular stiffness (in particular in large arteries)11, increased arterial pulse 
wave velocity (PWV) and early wave reflection12,  as well as dysregulation of the 
autonomic nervous system and the renin-angiotensin-aldosterone system (RAAS)10;13, 
progressive renal dysfunction14 and increase in salt sensitivity15, are important factors. 
Secondary causes of hypertension more rarely lead to ISH10;16. 
Placebo-controlled outcome trials (The Systolic Hypertension in the Elderly 
Program [SHEP]17, The Systolic Hypertension in Europe Trial [Syst-Eur]18 and The Systolic 
Hypertension in China Trial [Syst-China]19) have demonstrated that antihypertensive 
treatment of ISH is efficacious; cardiovascular morbidity and mortality was decreased by 
30-40% in patients who received antihypertensive therapy compared with placebo. 
Furthermore, all-cause mortality was reduced by 39% in the Syst-China trial19, but was 
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unaffected in the SHEP17 and Syst-Eur18 trials. The first comparative drug trial to report 
cardiovascular outcomes in ISH with ECG-LVH was a LIFE substudy20, demonstrating 
significantly lower rates of stroke and cardiovascular death in patients randomized to 
losartan- versus atenolol-based antihypertensive treatment. 
 
Left ventricular hypertrophy 
Left ventricular hypertrophy (LVH) is defined as an increase in the mass of the left ventricle. 
Hypertension causes increased afterload and left ventricular wall stress, which again leads to 
myocardial hypertrophy (increase in the number and/or size of sarcomeres within each 
myocardial cell). The prevalence of LVH in patients with hypertension depends on age, 
severity of hypertension and the method of detection; even in mild or moderate hypertension 
the prevalence may be as high as 20-50%21-24. 
LVH detected by 12-lead electrocardiogram (ECG)25-28 and by echocardiography29-35 
are common manifestations of preclinical cardiovascular disease that strongly predict 
cardiovascular morbidity and mortality. Several studies suggest that the increased 
cardiovascular risk associated with LVH is partly due to myocardial ischemia36-38.  
ECG-LVH can be measured by several methods; the most commonly used are, perhaps, 
Sokolow-Lyon voltage39 (SV1 + RV5/6) and Cornell voltage-duration product40;41 (QRS duration 
× the Cornell voltage combination [RaVL + SV3, with 6 mm added in women]). The threshold 
values for ECG-LVH are 38 mm for Sokolow-Lyon voltage and 2440 mm × ms for Cornell 
voltage-duration product.  
Antihypertensive therapy targeted at lowering BP can produce regression of 
LVH26;34;42-47 and reduce, but do not entirely eliminate the increased risk of major 
cardiovascular events48-52.  
 
Atrial fibrillation and pulse pressure 
AF is diagnosed by ECG and defined as a cardiac arrhythmia with: irregular RR intervals, i.e. 
RR intervals that do not follow a repetitive pattern; no distinct P waves; and usually a variable 
atrial cycle length, i.e. the interval between two atrial activations, <200 ms (>300 atrial bpm)53. 
The prevalence of AF increases with age and underlying heart disease54-57, and the total 
number of AF patients is increasing58. The lifetime risk for the development of AF was ~25% 
in the Framingham Heart Study59. AF is associated with a 4 to 5 fold increased risk of ischemic 
stroke60;61 and with a near doubled risk of cardiovascular death62. Hypertension is currently the 
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most prevalent, potentially modifiable risk factor, accounting for ~14% to 22% of AF cases63-
66. 
  Increased PP, defined as the difference between SBP and DBP, is a marker of 
arterial stiffness67;68. Studies have found brachial PP to be an independent predictor of new-
onset AF in both general69 and hypertensive70 populations. Furthermore, brachial PP is a 
predictor of cardiovascular morbidity and mortality71-77 (also in the LIFE study78) and its 
predictive effect increases with age74;75;77. 
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Aims of the thesis 
 
The aims of the thesis were, first, to investigate the effects of reducing ECG-LVH for 
cardiovascular morbidity and mortality in patients with ISH and ECG-LVH, and second, to 
investigate the relation between PP and new-onset AF in patients with hypertension and ECG-
LVH. The main hypotheses addressed were: 
 
x Lower in-treatment ECG-LVH is associated with lower risk of stroke, myocardial 
infarction and cardiovascular death in patients with ISH, and this effect is stronger in 
patients with ISH than in patients with systolic-diastolic hypertension or isolated 
diastolic hypertension. (Paper I) 
 
x Lower in-treatment ECG-LVH is associated with lower risk of new-onset HF and total 
mortality in patients with ISH, and this effect is stronger in patients with ISH than in 
patients with systolic-diastolic hypertension or isolated diastolic hypertension.  
(Paper II) 
 
x Higher baseline and in-treatment brachial PP is associated with higher risk of new-
onset AF in hypertensive patients with ECG-LVH, and PP is a stronger predictor of 
new-onset AF than other single BP components like SBP, DBP and MAP. (Paper 
III) 
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Materials and methods 
 
Study design and population 
The LIFE study is an investigator-initiated, prospective, multicenter, double-blinded, 
randomized, active-controlled, parallel-group trial79-81. The study was designed for 
comparing the long-term effects of losartan- vs. atenolol-based antihypertensive treatment 
on the primary composite endpoint of cardiovascular death, MI and stroke in patients with 
hypertension and ECG-LVH. Other outcome measures were the components of the primary 
composite endpoint (cardiovascular death, MI and stroke), total mortality, angina pectoris or 
heart failure requiring admission to hospital, coronary or peripheral revascularization 
procedures, resuscitated cardiac arrest, new-onset diabetes mellitus and new-onset atrial 
fibrillation. 
 The study enrolled 9193 patients aged 55-80 years with previously treated or 
untreated essential hypertension (mean sitting BP in the range of 160 to 200 mm Hg 
systolic, 95 to 115 mm Hg diastolic, or both, after one to two weeks of single-blind placebo 
treatment) having ECG-LVH determined by Cornell voltage-duration product40;41 and/or 
Sokolow-Lyon voltage criteria39 on a screening ECG. Patients were enrolled from June 
1995 to May 1997, in Norway, Sweden, Denmark, Finland, Iceland, USA and UK. 
Exclusion criteria were secondary hypertension; MI or stroke within the previous six 
months; angina pectoris requiring treatment with β-blockers or CCBs; heart failure or LVEF 
≤40%; or a disorder that, in the treating physician’s opinion, required treatment with an 
ARB, β-blocker, hydrochlorothiazide, or ACE-inhibitor. Patients were followed for 4 or 
more years with regular visits by 944 local investigators. The investigators followed a 
treatment schedule; with upward titration of medication targeting a BP of 140/90 mm Hg or 
lower79. The study was endpoint driven, follow-up was ended in September 2001 and the 
database was locked in December 2001. 
In the detailed LIFE data analysis plan that was submitted to the FDA in the USA 
before unblinding of the study, patients with ISH were prespecified as a subgroup of special 
interest20. ISH was defined as SBP ≥160 mm Hg and DBP <90 mm Hg after 1 to 2 weeks of 
receiving placebo. A total of 1320 ISH patients (14.4% of the LIFE population), averaging 
70.3 years, were included in the analyses when we investigated the possible effects of 
regression of ECG-LVH for the risks of the composite endpoint of cardiovascular death, MI 
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and stroke as well as the components of this endpoint (Paper I). We also performed a 
comparison of these results with those of the non-ISH patients (n=7873). 
When we investigated the possible effects of regression of ECG-LVH for the risks of 
new-onset HF and the combined endpoint of new-onset HF and all-cause mortality, we 
excluded patients with a history of HF (n=166) and thus 1280 ISH patients and 7747 non-ISH 
patients were eligible for data analyses (Paper II). 
We wished to examine whether pulse pressure was a predictor of new-onset AF in this 
study with 9193 patients with hypertension and ECG-LVH, and if PP was a stronger predictor 
than other BP components (Paper III). A total of 362 patients with a history of AF and/or AF 
on their baseline ECG and 21 patients with missing baseline PP were excluded and, thus, 8810 
patients with neither a history of AF or AF on their baseline ECG were included in the 
analyses.  
 
Ethics 
The trial protocol was approved by all ethics committees concerned; was in accordance with 
the Declaration of Helsinki and was overseen by an independent data and safety monitoring 
board79. All participants gave written informed consent. The investigators have the locked 
database in their position and the exclusive rights to analyze and publish. 
 
Procedures 
Brachial blood pressure was measured 24 hours after drug dose (range 22-26 hours) as the 
average of two recordings with a one-minute interval after patients had been seated for five 
minutes with the arm positioned so that the location of the stethoscope head was at the level 
of the heart. Investigators were instructed to use a validated, calibrated manual 
sphygmomanometer maintained in good condition and a cuff of proper size. In addition, 
one-minute standing BP was measured before upward titration of study drug; if orthostatic 
effect was observed, the investigator may have decided not to titrate to the next level82. 
Electrocardiograms were obtained at study baseline, at 6 months, and at yearly follow-
up intervals until study termination or patient death. All ECGs were read by experienced 
readers blinded to clinical information at the ECG core center at Clinical Experimental 
Research Laboratory, Department of Medicine, Sahlgrenska University Hospital/Östra, 
Göteborg, Sweden, under the leadership of Sverker Jern. QRS duration was measured to the 
nearest 4 ms and the QRS amplitudes to the nearest 0.5 mm (0.05 mV). The product of QRS 
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duration × the Cornell voltage combination (RaVL + SV3, with 8 mm added in women40;41 ) was 
used with a threshold value of 2440 mm × ms to identify LVH. The sex adjustment of Cornell 
voltage was reduced from 8 to 6 mm and Sokolow-Lyon voltage (SV1 + RV5/6) greater than 38 
mm was accepted for electrocardiographic eligibility in patients recruited after April 30, 1996 
(n=7708 in the LIFE study, including 1003 ISH patients)80;83. 
Laboratory tests were carried out at two central laboratories that assured 
comparability of measurements by cross-validation. The Framingham Risk Score was 
estimated from age, sex, SBP, total and high density lipoprotein cholesterol, smoking status, 
glucose/diabetes mellitus, and LVH84. 
 
Study endpoints 
All endpoints were reported by investigators and the source data was verified by 
independent monitors. An endpoint classification committee of two masked clinicians 
(Daniel Levy, USA and Kristian Thygesen, Denmark) reviewed clinical records of all 
reported cardiovascular events to determine whether they met endpoint criteria81. The 
committee used results from Minnesota coding of ECGs at the core laboratory for signs of 
MI or other disorders, however, they were blinded to study ECG-LVH findings when 
classifying possible morbid or mortal events. Deaths were reported directly to the 
independent data and safety monitoring board for validation81. Adverse experiences were 
monitored and classified as drug related or non-drug related and serious or non-serious. 
 We aimed to investigate the effect of regression of ECG-LVH on the primary 
composite endpoint of cardiovascular death, non-fatal MI and non-fatal stroke in ISH 
patients (Paper I). Furthermore, we wanted to evaluate the effect on the individual endpoints 
of cardiovascular death, fatal and non-fatal MI and fatal and non-fatal stroke (counting the 
first occurrence of each component of the primary composite endpoint, whether or not 
preceded by another component of the primary composite endpoint85). 
 Hospitalization for new-onset HF (Paper II) was based on the HF criteria from the 
Framingham Heart Study86;87 (Figure 1). Furthermore, a composite endpoint of new-onset 
HF or all-cause death (time to first event) was assessed for several reasons. First, death is a 
competing event and when comparing ISH to non-ISH it is essential to use the composite 
because of significant difference in mortality. Second, both incident HF and death were pre-
specified endpoints and combining them would increase the number of endpoints and the 
statistical power. Third, hypertension with LVH may be the most important source of HF 
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with subsequent high mortality26;88-101. Fourth, this composite has been the primary or 
secondary endpoint in many outcome trials in patients with HF102-105. 
New-onset AF was identified by Minnesota coding of annual in-study ECGs at the core 
laboratory79;85 (Paper III). New-onset AF was also reported as an adverse experience by study 
investigators, however, in our analyses we used a conservative approach and included only the 
ECG documented endpoints. Care of the patients with new-onset AF was left to the discretion 
of local investigators.  
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Figure 1. Hospitalization for new-onset heart failure criteria87 
(Modified from Supplementary online figure, Paper II) 
 
 
A definite diagnosis required a minimum of one major clinical plus one major diagnostic 
finding; or one major clinical plus two minor diagnostic findings; or one minor clinical plus 
two major or minor diagnostic findings. Minor criteria were only accepted if they could not 
be attributed to another disease process. LVEF, left ventricular ejection fraction. 
The Supplementary online figure is linked to the online version of Paper II at 
http://www.nature.com/ajh 
Major clinical findings 
- Paroxysmal nocturnal dyspnoea 
- Jugular venous distention 
- Pulmonary rales 
- Ventricular S3 gallop 
- Hepatojugular reflux 
- Diuresis of 10 pounds or 5 kg in 
response to diuretic treatment with 
clinical improvement in congestive 
symptoms 
 
 
Major diagnostic findings 
Chest X-ray 
- Acute pulmonary oedema 
Haemodynamic 
- Pulmonary capillary wedge 
pressure ≥20 mm Hg 
- LVEF ≤35% 
- Cardiac index <2.0 L/min 
- Evidence of severe valvular disease 
Autopsy 
- Pulmonary oedema, visceral 
congestion or cardiomegaly 
 
 
Minor clinical findings 
- Night cough 
- Dyspnoea on ordinary exertion 
- Bilateral ankle oedema 
- Hepatomegaly 
 
 
 
 
 
 
Minor diagnostic findings 
Chest X-ray 
- Pleural effusion or pulmonary 
vascular engorgement or 
redistribution 
Haemodynamic 
- Pulmonary capillary wedge    
pressure of 16-19 mm Hg 
- LVEF 36-44% 
- Cardiac index of 2.0-2.4 L/min 
- Evidence of moderate valvular 
heart disease 
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Statistical methods 
Statistical analyses were performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) 
following a prespecified data analysis plan. For all tests, a two-tailed P<0.05 was required 
for statistical significance. Data are presented as mean±standard deviation (SD) for 
continuous variables and as numbers (%) for categorical variables. Differences in baseline 
characteristics between groups were assessed by Student’s t-test or by analysis of variance 
(ANOVA) for continuous variables and chi-square test for categorical variables. To account 
for the within-subject correlations, general and mixed-effects linear models were used to 
compare annual measurements of mean BP and ECG-LVH. 
Only endpoints confirmed by the endpoint committee were included in the analyses. 
Analyses were based on the intention to treat principle81; all randomized patients were 
included in their treatment group and followed for endpoints for the duration of the study, 
regardless of protocol violations or adherence to study medication. Patients with multiple 
endpoints were counted as having had an event in all relevant endpoint analyses; however, 
only the first event in a specific category was counted in individual analyses. 
Cox proportional hazard regression models83;106 were used to examine possible 
associations between time-varying ECG-LVH and the risk of cardiovascular death, MI 
and/or stroke in ISH patients (Paper I); possible associations between time-varying ECG-
LVH and risk of new-onset HF and all-cause mortality in ISH patients (Paper II); and 
possible associations between baseline and time-varying PP and risk of new-onset AF in 
patients with hypertension and ECG-LVH (Paper III). Results were reported as HRs with 
95% CI. Initially, univariate analyses were performed using the predictor variable in 
question and other potential risk factors (baseline clinical, demographic and laboratory 
data). Multivariate analyses were then performed to identify predictors independently 
associated with the endpoints, adjusted for baseline Framingham Risk Score and a treatment 
group indicator, and time-varying systolic and/or diastolic BP as prespecified covariates. 
Additional covariates were selected based on being established risk factors or near 
significant univariate predictors (P<0.10), which continued to be significant (P<0.05) in 
stepwise forward and backward regression analyses. Interaction analyses were performed in 
order to test if the effect of regression of ECG-LVH was stronger in ISH than in non-ISH 
patients (Paper I and II), and if there were interactions between BP components and other 
risk factors for new-onset AF (Paper III). Atrial fibrillation event rates over time were 
illustrated by an unadjusted Kaplan-Meier curve (Paper III). 
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Summary of the results 
 
Paper I 
Electrocardiographic LVH and risk of cardiovascular morbidity and mortality in 
patients with ISH 
The predictive value of regression of ECG-LVH during antihypertensive therapy was 
investigated in 1320 patients (60.2% women) with ISH and ECG-LVH in the LIFE study. 
Mean BP at baseline was 174/83 mm Hg and 33.3% had previously untreated hypertension. 
The composite endpoint of cardiovascular death, non-fatal MI or non-fatal stroke occurred in 
179 (13.6%) patients during mean 4.8 years of follow-up. Fatal/non-fatal stroke, fatal/non-fatal 
MI and cardiovascular death occurred in 88 (6.7%), 67 (5.1%) and 79 (6.0%) patients. In Cox 
regression models controlling for treatment with losartan or atenolol, Framingham Risk Score 
and baseline and in-treatment SBP and DBP, regression of ECG-LVH by Cornell product and 
Sokolow-Lyon voltage were significantly associated with 17% (95% CI: 8-25%) and 25% 
(95% CI: 13-35%) risk reductions for the composite endpoint per SD reductions in Cornell 
product (1050 mm x ms) and Sokolow-Lyon voltage (10.5 mm). In parallel analyses evaluating 
the single endpoints cardiovascular death, fatal and non-fatal MI and fatal and non-fatal stroke; 
regression of Cornell product and Sokolow-Lyon voltage were significantly associated with 
lower risks of cardiovascular death and MI; and regression of Sokolow-Lyon voltage with 
lower risk of stroke. There was a significant interaction (P=0.048) between regression of 
Sokolow-Lyon voltage and lower risk of the composite endpoint of cardiovascular death, non-
fatal MI or non-fatal stroke in ISH versus non-ISH patients; ISH patients had an increased 
outcome effect of regression of Sokolow-Lyon voltage as compared with non-ISH patients. 
 
Paper II 
Electrocardiographic LVH and risk of new-onset heart failure and all-cause mortality 
in patients with ISH 
In 9027 patients without a history of HF in the LIFE study, the predictive effects of 
regression of ECG-LVH for incident HF and the combined endpoint of HF and death were 
evaluated in 1280 ISH patients and as compared with 7747 non-ISH patients. During mean 
follow-up of 4.8±0.9 years, new-onset HF and HF or death occurred in 57 (4.5%) and 179 
(14.0%) ISH patients and in 220 (2.8%) and 787 (10.2%) non-ISH patients. Cox regression 
analyses adjusting for treatment with losartan or atenolol and HF risk factors, showed that 
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regression of time-varying Cornell product was significantly associated with lower risks of 
new-onset HF and the combined endpoint of new-onset HF and death in patients with ISH 
and non-ISH. Regression of Sokolow-Lyon voltage was not associated with lower risk of 
new-onset HF in ISH, neither in crude (P =0.22) nor adjusted (P=0.84) analyses. However, 
it was significantly associated with the combined endpoint of new-onset HF and death in 
ISH, and with both new-onset HF and the combined endpoint in non-ISH. There was a 
borderline significant interaction for new-onset HF (P=0.050) between time-varying Cornell 
product and ISH status, but not for the combined endpoint of HF and death (P=0.53). 
 
Paper III 
Pulse pressure and risk of new-onset atrial fibrillation in patients with hypertension 
and ECG-LVH 
We examined whether PP, the pulsatile component of BP and a marker of arterial stiffness, 
predicted new-onset AF in comparison with other BP components in the LIFE study. In 8810 
patients with hypertension and ECG-LVH and neither a history of AF or AF at baseline, 
Minnesota coding of ECGs confirmed new-onset AF in 353 patients (4.0%) during mean 4.9 
years of follow-up. In multivariate Cox regression analyses increase in baseline and in-
treatment PP and baseline and in-treatment SBP predicted new-onset AF, independent of 
baseline age, height, weight and Framingham Risk Score; gender, race and treatment with 
losartan or atenolol; and in-treatment heart rate and Cornell product. PP was the strongest 
single BP predictor of new-onset AF determined by the decrease in the -2 Log likelihood 
statistic (a measure of model agreement with data) in comparison with SBP, DBP and MAP. 
When evaluated in the same model, the predictive effects of SBP and DBP together were 
similar to that of PP. 
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Discussion 
 
Paper I and II 
In these LIFE reports regarding patients with ISH and ECG-LVH, the results of Cox regression 
analyses showed significant associations between regression of Cornell voltage-duration 
product and/or Sokolow-Lyon voltage criteria during antihypertensive therapy and improved 
cardiovascular outcomes, independent of other risk factors and treatment modality. To our 
knowledge, this is the first time results of regression of ECG-LVH during antihypertensive 
treatment have been reported in patients with ISH. 
Regression of time-varying Cornell voltage-duration product per 1050 mm x ms (1 SD) 
was independently and significantly associated with a 17% reduced risk of the primary 
composite endpoint of cardiovascular death, non-fatal MI and non-fatal stroke; a 25% reduced 
risk of cardiovascular death and a 17% reduced risk of fatal and non-fatal MI (Paper I); and an 
21% reduced risk of new-onset HF and a 17% reduced risk of the combined endpoint of new-
onset HF or all-cause death (Paper II). Regression of time-varying Cornell product was not 
associated with reduced risk of stroke (P=0.96) (Paper I). This result deviated from the 
significant 10% risk reduction for stroke associated with regression of Cornell product in the 
total LIFE population83 and may represent a type II error due to lack of power (power 
calculations were based on the primary composite endpoint and not its components). 
Furthermore, there was a borderline significant interaction (P=0.050) between ISH status and 
time-varying Cornell product for new-onset HF possibly indicating a greater outcome effect of 
regression of Cornell product in patients with non-ISH (33% risk reduction) as compared with 
ISH (21% risk reduction) (Paper II). This finding may be subject to a type II error due to low 
statistical power, and perhaps it should be statistically significant (P<0.05). In regard to the 
combined endpoint of HF or all-cause death, regression of time-varying Cornell product was 
independently associated with similar significant risk reductions in both subsets of 
hypertensive patients. 
Regression of time-varying Sokolow-Lyon voltage per 10.5 mm (1 SD) was 
independently and significantly associated with a 25% reduced risk of the composite 
cardiovascular endpoint; a 28% reduced risk of cardiovascular death; a 23% reduced risk of 
fatal and non-fatal MI and a 25% reduced risk of fatal and non-fatal stroke (Paper I). 
Interaction analyses indicated an increased outcome effect of regression of Sokolow-Lyon 
voltage for the composite cardiovascular endpoint in ISH versus non-ISH patients (P=0.048 for 
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the interaction cross-product). Regression of time-varying Sokolow-Lyon voltage was not 
associated with reduced risk of new-onset HF in ISH (P=0.84), perhaps due to lack of power. It 
was, however, significantly associated with a 20% reduced risk of the combined endpoint of 
new-onset HF or all-cause death (Paper II). Furthermore, in patients with non-ISH, time-
varying Sokolow-Lyon voltage was significantly associated with a 26% lower risk of new-
onset HF and a 20% lower risk of new-onset HF or death per 10.5 mm regression (Paper II).  
It is important to note that regression of ECG-LVH was computed per SD reduction in 
ECG-LVH indices for the total LIFE population; i.e. 1050 mm x ms for Cornell voltage-
duration product and 10.5 mm for Sokolow-Lyon voltage. This made findings comparable with 
effect sizes from previous LIFE study reports when plausible; overall the effect sizes of 
regression of ECG-LVH for most cardiovascular endpoints were quite large (17-28% risk 
reductions during mean 4.8 years of follow-up) and larger than effect sizes in parallel analyses 
in the total population83. In our opinion, these effect sizes were of clinical significance.  
Our results suggest superior performance for time-varying Sokolow-Lyon voltage 
compared to Cornell product for prediction of cardiovascular endpoints in patients with ISH 
compared with non-ISH. A possible explanation for this may be that Sokolow-Lyon voltage 
LVH is strongly associated with systolic BP and therefore ISH, whereas Cornell product is 
more related to metabolic risk factors107. In addition, it may be of importance how the 
Sokolow-Lyon criteria were originally developed; in the Veteran Administration population of 
hypertensive patients, a majority of patients had quite severe hypertension with a high 
contribution of patients with ISH39.  
In a study evaluating the prognostic significance of serial ECG voltage in 4,159 
patients with ISH enrolled in the Syst-Eur trial93, Fagard et al found a strong association 
between baseline ECG left ventricular mass defined as the sum of voltages (RaVL+SV1+RV5) 
and new-onset HF, but decrease in the sum of voltages was not a significant predictor of 
lower HF incidence in multivariate Cox models. Thus, the Syst-Eur findings were consistent 
with our present finding in LIFE ISH patients; that regression of ECG voltage alone 
(Sokolow-Lyon criteria) was not associated with lower incidence of HF. Our findings do not 
exclude that regression of LVH by voltage criteria (e.g. Sokolow-Lyon) is important since 
the majority of our participants were recruited by having LVH with Cornell product 
criteria80. Furthermore, the interaction analyses showed borderline significance (p=0.050) 
for stronger association between regression of Cornell product and reduced risk of HF in 
non-ISH than in ISH patients. Combining the Syst-Eur voltage data93, and our Sokolow-
Lyon findings in the present study, this finding may overall rank ISH patients somewhat 
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weaker than non-ISH patients in using ECG-LVH regression to predict incident HF. In 
variance to the Sokolow-Lyon voltage findings in Syst-Eur and in this study, regression of 
Cornell product was clinically useful for both new-onset HF and the combined endpoint in 
both ISH and non-ISH populations. The use of hospitalization for new-onset HF to define 
HF, probably underestimates the true incidence, which again may attenuate the precision of 
the results.   
Our data indicate that the regression of Cornell product may reach a nadir earlier than 
the regression of Sokolow-Lyon voltage in patients with ISH (Paper I, Figure 2b). In a 
previous LIFE report, it was indicated that the two ECG-LVH indices recruit different groups 
of patients107, and perhaps these groups of patients respond somewhat differently to 
antihypertensive treatment with respect to regression of ECG-LVH. Overall, these data support 
the view that both ISH and non-ISH patients should be carefully monitored for regression of 
ECG-LVH by both Cornell product and Sokolow-Lyon criteria during the treatment of 
hypertension. 
LVH demonstrated by ECG and echocardiography is a strong predictor of 
cardiovascular disease30 and particularly of cerebrovascular events108. Previous studies have 
shown that prevention and regression of both indices of LVH are associated with improved 
prognosis25;26;46;51;83;109. Echocardiography is preferred in assessing LVH and changes in left 
ventricular mass owing to low sensitivity of standard voltage criteria (i.e. Sokolow-Lyon 
voltage) for detecting LVH23;39-41;110-115. However, the use of Cornell voltage-duration 
product (as an approximation of the true area under the QRS complex) enhances sensitivity 
of the ECG to ~51%, with a matched specificity of ~95%40;41;110;111;114. The LIFE study was 
the first prospective study with adequate statistical power to link regression of LVH to 
reduction of major cardiovascular events; however, this required a large number of patients 
which was feasible to recruit by ECG and not echocardiography79. The presence of Cornell 
product and/or Sokolow-Lyon voltage criteria, identified hypertensive patients with >70% 
likelihood of having echocardiographic LVH as well as those not meeting the strict criteria 
for echocardiographic LVH but with high normal values of indexed left ventricular 
mass116;117, allowing accurate identification of high-risk status by these ECG indices. 
Furthermore, regression of Cornell product was associated with greater 1-year reductions in 
left ventricular mass and a higher likelihood of regression of echocardiographic LVH45. 
Regression of both Cornell product and Sokolow-Lyon voltage were independently 
associated with reduced risk of major cardiovascular endpoints83 and lower values of 
indexed left ventricular mass were associated with a 22% reduced risk of the composite 
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cardiovascular endpoint and 15-35% reduced risks of MI, stroke and cardiovascular 
death109. Evaluated together, these ECG and echocardiographic findings indicate that there 
are strong associations between serial assessments of LVH and cardiovascular outcomes 
independent of the method used to serially evaluate the degree of LVH. In our opinion, the 
internal validity was high for the serial ECG assessments used in evaluating cardiovascular 
outcomes in this LIFE substudy with ISH patients. Unfortunately, we could not evaluate the 
degree of correlation between serial measurements of electrocardiographic and 
echocardiographic LVH in ISH as there were very few patients with ISH in the 
echocardiography substudy (n=145, 11% of total ISH population). It is important to note 
that ECG, albeit having lower sensitivity and positive and negative predictive values, is a 
less expensive and much more available technique compared with echocardiography116. 
 
Paper III 
Increased baseline brachial PP and time-varying PP were independently associated with an 
increased risk of incident AF independent of other predictors of AF in this population. In 
comparison with SBP, DBP and MAP as single BP components, PP was the strongest predictor 
of incident AF based on the decrease in -2 Log likelihood statistic. To our knowledge this is 
the first study to report a strong, independent association between brachial PP and new-onset 
AF in patients with hypertension and ECG-LVH.  
 Both men and women have an approximate 25% overall lifetime risk of developing 
AF59. AF is a cardiac arrhythmia associated with increased risk of cardiovascular morbidity 
and mortality, and it is, therefore, important to identify modifiable risk factors. These results 
are in agreement with a Framingham Heart Study report evaluating PP as a predictor for 
incident AF in a general population with normal or moderately increased BP69, which 
demonstrated that there is a potential weakness of concentrating on SBP alone and ignoring 
DBP and PP. 
Increased PP, a marker of advanced vascular ageing and arterial stiffness67;118;119, 
may contribute in the structural and electrical remodeling of the myocardium leading to the 
development of AF, possibly through increased pulsatile load on the heart and increased left 
atrial size120. Studies have shown that reduced distensibility of large arteries parallel cardiac 
hypertrophy and remodeling in hypertensive patients121;122. Large artery stiffness may 
increase the work load on the heart similar to volume overload and perhaps represent one of 
the mechanisms by which hypertension leads to eccentric hypertrophy and left atrial 
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enlargement122. Studies have linked brachial PP to microvascular damage in the heart and 
other target organs, which again may lead to increased peripheral resistance and MAP, 
further increasing arterial stiffness and central PP. Increased central PP may then further 
damage small arteries and lead to LVH123. Brachial PP is a powerful predictor of 
cardiovascular morbidity and mortality in several studies71-78, and its predictive effect 
increases with age74;75;77. The present study evaluated brachial PP and not central PP. 
Noninvasive central PP has been shown to better predict cardiovascular outcomes than 
brachial PP; and to be closer associated with extent of atherosclerosis (carotid plaque burden 
and intimal-medial thickness, and vascular mass)124.  
BP was measured with sphygmomanometer, which is considered less accurate than 
24-hour ambulatory BP measurement74. Analyses of new-onset AF was planned as a 
secondary endpoint before study termination (September 2001) and unblinding, and not in 
the 1995 LIFE data analysis plan125, however the LIFE study was designed and had 
statistical power for the primary composite endpoint and the HRs for AF require careful 
interpretation. Annual ECGs may be more sensitive for detecting sustained AF (i.e. 
persistent or permanent AF) than for paroxysmal AF. When diagnosing new-onset AF by 
annual ECGs interpreted at a core laboratory, we most likely missed some instances of 
paroxysmal AF. 
 
General discussion 
This was a substudy of a large multicenter, randomized controlled trial (RCT) in high-risk 
patients with hypertension and ECG-LVH, in which ISH patients were selected a priori as 
being of special interest as they are a group of hypertensive patients with especially high risk. 
Therefore, some possible limitations in the external validity merit discussion. The LIFE ISH 
patients described here, all had SBP >160 mm Hg and DBP <90 mm Hg, comparable to ISH 
grade II-III in the current ESH-ESC guidelines126. Therefore, it is uncertain whether the results 
are generalizable to patients with ISH grade I, i.e. SBP  >140 mm Hg and DBP <90 mm Hg. 
Patients included had hypertension and ECG-LVH, and the results may not be generalizable to 
ISH patients without LVH, to patients with systolic-diastolic hypertension without LVH or to 
normotensives. In this context, it is important to note that the prevalence of ECG-LVH in a 
Finnish study of 1746 ambulatory patients with hypertension was 9.8% in men and 5.7% in 
women for Sokolow-Lyon voltage and 14.9% and 18.8%, respectively, for Cornell product 
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criteria127. Patients evaluated in the LIFE study were predominantly white and from countries 
in Northern Europe and the USA. 
In a comprehensive trial like the LIFE study, some statistical considerations should be 
discussed. Although being a substudy of a comparative antihypertensive trial, in these analyses 
we adjusted for treatment and did not compare effects of the two treatment regimes. When 
performing several statistical analyses on the same data, some results, albeit statistically 
significant, may not be clinically relevant. Moreover, there may be type I errors, i.e. significant 
test result when the null hypothesis in fact is true. However, our results were consistent in 
different univariate and multivariate Cox regression models, were in coherence with previous 
results in the LIFE study, and seemed robust and reliable. Furthermore, it is of great 
importance to keep in mind that results of regression analyses, demonstrate an association 
between the dependent and independent variables and does not necessarily imply causality. 
Also, the analyses of time-varying ECG-LVH and BP during antihypertensive treatment were 
prespecified and prospective, and adjustment for Framingham Risk Score was selected a priori 
primarily to account for any difference in key risk factors at baseline. Additional adjustments 
were based on findings in the univariate analyses (Paper I, II and III), of which some were 
retrospective of nature (i.e. assessment of baseline predictors of outcomes in the patients 
included in present analyses). In addition to the main predictor variables, covariates in the 
multivariate models were selected based on being near significant univariate predictors 
(P<0.10) which continued to be significant predictors in stepwise forward and backward 
regression analyses (P<0.05), unless otherwise specified. The total number of covariates in the 
multivariate models did not exceed 10% of the number of events for the endpoint in 
question128. Furthermore, the phenomenon of regression to the mean may impact the current 
findings83;129, in regard to the use of values of Cornell product and Sokolow-Lyon voltage 
above threshold levels to include patients. We attempted to minimize this problem by using 
separate screening and baseline ECGs79;80. Due to this selection process and the intrinsic 
variability of ECG measurements129-132, it is likely that both the degree of ECG-LVH at 
baseline and the subsequent decrease in LVH during therapy were overestimated in some 
patients. Despite these limitations, improved outcome was associated with lower ECG-LVH, 
which would actually bias against our findings, as these overestimations due to statistical 
fluctuations would lead to a more conservative estimate of the impact of ECG-LVH on 
outcome. Furthermore, assessment of risk based on ECG-LVH criteria considered as time-
varying covariates adjusts for both baseline and subsequent levels of these variables, mitigating 
the impact of any overestimations83. When also taking into account that the sample size and 
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power calculations for the main LIFE study were based on a 15% reduction in the 5-year event 
rate of the primary composite endpoint for losartan versus atenolol, it is important to stress that 
the hazard ratios for the cardiovascular outcomes in these analyses require careful 
interpretation. 
 
Clinical implications 
Our results support the use of Cornell product and Sokolow-Lyon voltage criteria to identify 
ISH patients who are most likely to benefit from aggressive antihypertensive therapy, and 
indicate that targeting antihypertensive treatment at regression or prevention of ECG-LVH, and 
beyond that of lowering BP, may reduce cardiovascular morbidity and mortality in patients 
with ISH (Paper I and II). This study supports serial measurements of ECG-LVH for risk 
stratification in patients with ISH undergoing antihypertensive therapy in order to improve 
their prognosis. 
Furthermore, our results support the hypothesis that the relation between BP and 
incident AF is related specifically to the pulsatile component of BP as assessed by PP69,  and 
imply that the association between MAP, i.e. the steady component of BP, and AF, is weak 
(Paper III). When evaluating risk of AF in hypertensive patients with ECG-LVH, both baseline 
PP and PP during antihypertensive treatment, alternatively SBP and DBP together, should be 
considered. Furthermore, lowering of PP may prevent new-onset AF in hypertensive patients 
with LVH.  
 
Future perspectives 
In the past, high BP has been regarded as a normal trait of ageing. It is now evident that 
hypertension in older individuals, defined by current guidelines10;126 is associated with 
increased risk of cardiovascular outcomes like coronary heart disease, congestive heart 
failure, stroke, peripheral vascular disease, renal disease and mortality. Hypertension in the 
elderly is not benign and should be properly diagnosed and treated. More studies are needed 
to further elucidate the pathophysiology of ISH and increased pulse pressure; to further 
evaluate if treatment should be targeted at regression of ECG-LVH in patients with ISH, and 
not only at specific BP values; and to further evaluate if reduced PP prevents incident AF. 
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Conclusions 
 
Paper I  
Regression of ECG-LVH determined by Cornell voltage-duration product and Sokolow-Lyon 
voltage, were significantly associated with lower risks of cardiovascular morbidity and 
mortality, independent of treatment modality, baseline Framingham Risk Score and time-
varying SBP and DBP in patients with ISH and ECG-LVH. ISH patients had an increased 
outcome effect of regression of Sokolow-Lyon voltage for the composite endpoint of 
cardiovascular death, MI and stroke as compared with non-ISH patients. 
 
Paper II 
Regression of ECG-LVH determined by Cornell voltage-duration product was associated 
with similar significant reductions in risk of new-onset HF and the combined endpoint of 
HF or all-cause mortality in ISH and non-ISH patients, independent of treatment modality, 
baseline Framingham Risk Score and UACR, history of AF and time-varying SBP. 
 
Paper III 
Increased baseline and in-treatment PP were associated with increased risk of new-onset AF in 
patients with hypertension and ECG-LVH, independent of baseline age, height, weight and 
Framingham Risk Score; gender, race and treatment modality; and time-varying heart rate and 
ECG-LVH by Cornell voltage-duration product. As compared with SBP, DBP and MAP, PP 
was the single BP component with the strongest predictive effect. 
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